Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07190209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07190209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Recruiting
Start date
September 16, 2025
Completion date
January 22, 2030
Enrollment
942 (estimated)
Sites
294

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease